NCT05594706 Anhydroglucitol in Children With Type 1 Diabetes
| NCT ID | NCT05594706 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Geneva |
| Condition | Diabetes Mellitus, Type 1 |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-01-27 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2023-01-27 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators will measure blood levels of 1,5-anhydroglucitol in children with type 1 diabetes and correlate them with parameters related to functional beta-cell mass in diabetic patients. The values will be compared to those obtained in healthy volunteers. Children with newly diagnosed diabetes as well as children with longstanding disease will be included. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in type 1 diabetes.
Eligibility Criteria
Inclusion Criteria: * Type 1 diabetes with positive autoantibodies against islets, insulin, islet antigen 2 (IA2), glutamic acid decarboxylase (GAD) 65 or zinc transporter (ZnT)8. * Treatment with continuous subcutaneous insulin infusion (CSII) with or without automated insulin delivery (AID). * Monitoring with a continuous glucose measurement system (CGMS) or flash glucose monitor (FGM). * Patient willing to keep the same type of CGMS or FGM during the year of observation * Ability to give informed consent as documented by signature Exclusion Criteria: * Patients treated with multiple daily injections (MDI) or not willing to wear a CGMS of FGM * Patients changing the type of CGMS during the course of the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05594706 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 18 Years, studying Diabetes Mellitus, Type 1. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05594706 currently recruiting?
Yes, NCT05594706 is actively recruiting participants. Contact the research team at philippe.klee@unige.ch for enrollment information.
Where is the NCT05594706 trial being conducted?
This trial is being conducted at Geneva, Switzerland.
Who is sponsoring the NCT05594706 clinical trial?
NCT05594706 is sponsored by University Hospital, Geneva. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.